{"id":"rc28-e","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"1-5%","effect":"Pneumonitis"}]},"_chembl":{"chemblId":"CHEMBL83060","moleculeType":"Small molecule","molecularWeight":"448.59"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"RC28-E works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells and thereby enhancing the immune response against cancer cells.","oneSentence":"RC28-E is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:18.561Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT04782115","phase":"PHASE2","title":"Evaluation of RC28-E Injection in Diabetic Macular Edema","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2021-03-17","conditions":"Diabetic Macular Edema","enrollment":156},{"nctId":"NCT04782128","phase":"PHASE2","title":"Evaluation of RC28-E Injection in Diabetic Retinopathy","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2021-05-25","conditions":"Diabetic Retinopathy","enrollment":120},{"nctId":"NCT05885503","phase":"PHASE3","title":"Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-06-08","conditions":"Diabetic Macular Edema","enrollment":316},{"nctId":"NCT05727397","phase":"PHASE3","title":"Efficacy and Safety of RC28-E Versus Aflibercept","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2023-03-14","conditions":"Wet Age-related Macular Degeneration","enrollment":432},{"nctId":"NCT04270669","phase":"PHASE1, PHASE2","title":"Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2020-04-15","conditions":"Wet Age-Related Macular Degeneration","enrollment":37},{"nctId":"NCT03777254","phase":"PHASE1","title":"Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-01-07","conditions":"Neovascular Age-related Macular Degeneration","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RC28-E is a chimeric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2."],"phase":"phase_3","status":"active","brandName":"RC28-E","genericName":"RC28-E","companyName":"RemeGen Co., Ltd.","companyId":"remegen-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RC28-E is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}